However, in a stratified analysis of women in the two categorical HIV disease stage groups (CD4<200 and CD4>200) receiving either ZDV or triple ARV regimen, the risk for anaemia was not statistically significant for any particular group (Table 3). The gene discussed is CD4; the disease is anemia (phenotype).